Tofacitinib

Latin American patients with rheumatoid arthritis experience fewer serious adverse events, including major adverse cardiovascular events and malignancy, than patients who are not Latin American, according to a study.

Tofacitinib’s benefits in patients with juvenile idiopathic arthritis extend through at least 48 months, with no new safety findings, according to data published in Annals of the Rheumatic Diseases.

Tofacitinib “should be considered as a treatment option” for patients with refractory celiac disease type 2 who previously failed treatment with therapies such as budesonide, according to data in Clinical Gastroenterology and Hepatology.

In this video, Raymond Cross, MD, spoke with Healio about several studies assessing the safety and efficacy of JAK inhibitors in patients with IBD presented at Digestive Disease Week 2024.

WASHINGTON — Nearly 60% of patients with acute severe ulcerative colitis responded to Xeljanz 10 mg twice daily by day 7, with one-third of patients in steroid-free remission by 6 months, according to interim analysis data presented here.

Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors as first-line treatment among patients with severe ulcerative colitis, according to survey results.

Patients receiving daily tofacitinib doses of 10 mg for rheumatoid arthritis demonstrate an increased risk for venous thromboembolism and pulmonary embolism, compared with those taking TNF inhibitors, according to data.

Tofacitinib improves enthesitis in patients with psoriatic arthritis regardless of severity or location at baseline, according to data published in Arthritis Research and Therapy.